Goldman Sachs analyst Matthew Sykes raised the firm’s price target on Cytek Biosciences (CTKB) to $5.25 from $4.50 and keeps a Sell rating on the ...

Cytek Biosciences announced that its Board of Directors has approved a share repurchase plan on Monday, December 30th that permits the company to repurchase $50.00 million in outstanding shares.

FREMONT, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following ...

Cytek Biosciences, Inc. is a life sciences technology company, which engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS ...

FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report ...

Goldman Sachs has downgraded Cytek Biosciences (NASDAQ:CTKB) to sell from buy, citing increased competition and end market challenges. The investment bank said it believes consensus expectations ...

The Goldman Sachs Group cut shares of Cytek Biosciences (NASDAQ:CTKB – Free Report) from a buy rating to a sell rating in a research report sent to investors on Friday, Marketbeat Ratings reports.

On Friday, Goldman Sachs analyst Matthew Sykes downgraded Cytek Biosciences Inc (NASDAQ:CTKB) stock rating from Buy to Sell and reduced the price target to $4.50 from the ...

Cytek Biosciences, Inc. (CTKB) stock price is 5.15 and Cytek Biosciences, Inc. (CTKB) 10-day simple moving average is 5.71. Cytek Biosciences, Inc. (CTKB) stock price is 5.15 and Cytek Biosciences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...